Hypogonadism Clinical Trials

16 recruiting

Hypogonadism Trials at a Glance

31 actively recruiting trials for hypogonadism are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Boston, Jacksonville, and Bethesda. Lead sponsors running hypogonadism studies include Stephanie B. Seminara, MD, National Institute of Environmental Health Sciences (NIEHS), and Aarhus University Hospital.

Browse hypogonadism trials by phase

Treatments under study

About Hypogonadism Clinical Trials

Looking for clinical trials for Hypogonadism? There are currently 16 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hypogonadism trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hypogonadism clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 31 trials

Recruiting

Inherited Reproductive Disorders

InfertilityHypogonadismAmenorrhea+1 more
National Institute of Environmental Health Sciences (NIEHS)850 enrolled2 locationsNCT01500447
Recruiting

MEHMO Natural History and Biomarkers

ObesityEpilepsyHypogonadisms+3 more
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)150 enrolled1 locationNCT06019182
Recruiting
Phase 2

Testosterone Treatment in Men With Chronic Kidney Disease

Hypogonadism, MaleKidney Disease, Chronic
St. Louis University20 enrolled1 locationNCT05249634
Recruiting

Male Experiences With Intra Cytoplasmic Sperm Injection (ICSI) and Reduced Sperm Quality

Quality of LifeHypogonadismSocial Interaction+3 more
Peter Humaidan400 enrolled1 locationNCT07546435
Recruiting
Phase 2

Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism

PainOpioid UseHypogonadism, Male
Brigham and Women's Hospital150 enrolled1 locationNCT04798469
Recruiting
Phase 2

Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency

CancerFatigueHypogonadism, Male
Seattle Institute for Biomedical and Clinical Research230 enrolled3 locationsNCT04301765
Recruiting
Phase 3

52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism

Hypogonadism, Male
Halozyme Therapeutics100 enrolled20 locationsNCT06689085
Recruiting
Not Applicable

REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)

NeoplasiaOsteoporosisOsteogenesis Imperfecta+1 more
Meyer Children's Hospital IRCCS100 enrolled1 locationNCT07412782
Recruiting
Not Applicable

EndoPAT Device for Endothelial Dysfunction in ED

Hypogonadism, MaleErectile DysfunctionEndothelial Dysfunction
University of California, Irvine120 enrolled1 locationNCT06720597
Recruiting
Phase 2

Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea

Hypogonadotropic HypogonadismHypothalamic Amenorrhea
Stephanie B. Seminara, MD20 enrolled1 locationNCT07224438
Recruiting

Observation of Environment and Reproductive-Endocrine Effects

HypogonadismPrecocious PubertyAmenorrhea+2 more
National Institute of Environmental Health Sciences (NIEHS)300 enrolled1 locationNCT06280807
Recruiting

Perception of Hormonal Replacement Therapy Among Patients Aged 11 to 17 Years

Female Hypogonadism
University Hospital, Strasbourg, France20 enrolled1 locationNCT07315932
Recruiting

The REgistry of Very Early Estrogen and AnovuLation

Hypothalamic AmenorrheaHypothalamic Amenorrhea, FunctionalFunctional Hypogonadotropic Hypogonadism
Mayo Clinic100,000 enrolled2 locationsNCT06583408
Recruiting
Phase 2

Kisspeptin Administration Subcutaneously to Patients With IHH

Hypogonadotropic Hypogonadism
Stephanie B. Seminara, MD36 enrolled1 locationNCT05896293
Recruiting

The Effect of Sex Steroid Replacement Therapy in the Hypogonadism and Transgender Active-Duty Population

HypogonadismGender Identity Dysphoria
Walter Reed National Military Medical Center75 enrolled1 locationNCT06247267
Recruiting

The Molecular Basis of Inherited Reproductive Disorders

Kallmann SyndromeHypogonadotropic HypogonadismReproductive Disorder+1 more
Stephanie B. Seminara, MD600 enrolled1 locationNCT05971836
Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

Rare DisordersUndiagnosed DisordersDisorders of Unknown Prevalence+188 more
Sanford Health20,000 enrolled2 locationsNCT01793168
Recruiting

IMmune checkPoint inhibitor related gonAdal toxiCiTy in premenopausal women and men with melanoma – the IMPACT study

MelanomaMenopauseHypogonadism
Peter MacCallum Cancer Centre80 enrolled6 locationsACTRN12625000395437
Recruiting
Phase 2

Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury

Central Nervous System DiseasesGenital Diseases, MaleHypogonadism+17 more
North Florida Foundation for Research and Education21 enrolled2 locationsNCT04460872
Recruiting
Phase 3

Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy

Prostatic NeoplasmsHypogonadismTestosterone Deficiency
Canisius-Wilhelmina Hospital140 enrolled10 locationsNCT04833426